Preeclampsia Market Size and Share Outlook Report: Forecast Trends and Growth Analysis (2026-2035)

Preeclampsia Market Overview

Preeclampsia is a pregnancy-related condition marked by high blood pressure and signs of organ damage, typically after 20 weeks of gestation. It is one of the most commonly reported complications during pregnancy, affecting approximately 2% to 15% of all pregnancies. It can affect the liver, kidneys, and other systems, posing risks to both mother and baby. Early diagnosis and proper management are crucial to prevent complications, including premature birth, organ failure, or progression to life-threatening eclampsia. The market is anticipated to grow at a CAGR of 8.10% during the forecast period of 2026-2035.

Preeclampsia Market Growth Drivers

RNA-Based Diagnostics to Boost Market Growth

Rising maternal mortality rates and the increasing prevalence of hypertensive pregnancy disorders are driving demand for early diagnostic tools in the preeclampsia market. For instance, in April  2025, a groundbreaking study published in Nature Communications by Mirvie revealed RNA signatures that can distinguish between severe and mild hypertensive pregnancy disorders months before symptoms appear. Using data from 9,000+ pregnancies, the findings are expected to accelerate the development of predictive diagnostics, enabling early intervention and significantly improving preeclampsia management outcomes during the forecast period.

Awareness Campaigns Enhancing Preeclampsia Market Development Outlook

The high incidence of preeclampsia and growing maternal health disparities are key concerns shaping the market. For instance, in March  2025, the Preeclampsia Foundation partnered with Patients & Purpose to launch GAP-SPIRIN, an educational campaign advocating the use of low-dose aspirin to prevent preeclampsia, particularly among high-risk groups like Black expectant mothers. This initiative is poised to boost preventive treatment adoption, promote equitable care, and significantly contribute to the development of the preeclampsia therapeutics market over the coming years.

Preeclampsia Market Trends

Preeclampsia Market Segmentation

Preeclampsia Market Share

Severe Preeclampsia to Lead the Market Share by Type

Severe preeclampsia is anticipated to lead the segment by type due to its high clinical urgency and associated complications, which demand intensive medical intervention. Rising awareness, better diagnostics, and an increase in high-risk pregnancies are driving diagnosis rates. This segment is poised for notable growth as healthcare systems prioritize early detection and aggressive management, thereby contributing significantly to the overall preeclampsia market expansion during the forecast period.

Antihypertensives to Hold a Substantial Preeclampsia Market Value for Segmentation by Treatment

Antihypertensives are expected to dominate the treatment segment as they are the primary line of defense in controlling maternal blood pressure. Their broad availability, affordability, and immediate therapeutic effect make them indispensable in managing preeclampsia. With rising global hypertension cases among pregnant women and ongoing innovation in drug formulations, this segment is projected to experience consistent growth, fuelling overall market development in the coming years.

Oral Route to Lead the Segmentation by Route of Administration

The oral route is likely to hold the largest market share owing to its convenience, better patient compliance, and wide availability of antihypertensive and corticosteroid formulations in oral form. The shift toward outpatient care and at-home management of mild preeclampsia cases supports this trend. As pharmaceutical advancements enhance oral drug delivery efficiency, the segment is expected to sustain its dominance and boost market value over the forecast period.

Preeclampsia Market Analysis by Region

The United States is expected to hold the largest market share in the preeclampsia market due to its advanced maternal healthcare system, high prevalence of hypertensive disorders in pregnancy, and strong government support for prenatal programs. 

According to the World Health Organization, pre-eclampsia and eclampsia contribute to around 10% of maternal deaths in Asia and Africa, and up to 25% in Latin America. Countries like the United Kingdom and Germany are focusing on early screening initiatives, while Japan benefits from an aging maternal population. Meanwhile, India shows growth potential through rising awareness, though access disparities limit rapid expansion compared to developed nations.

Leading Players in the Preeclampsia Market

Other key players in the market include Sanofi, Boehringer Ingelheim, AstraZeneca plc, Daiichi Sankyo, Teva Pharmaceutical Industries Ltd., and Lupin.

Key Questions Answered in the Preeclampsia Market

• What was the preeclampsia market value in 2025? 
• What is the preeclampsia market forecast outlook for 2026-2035?
• What are the major factors aiding the preeclampsia market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major preeclampsia market trends?
• Which type will lead the market segment?  
• Which treatment will lead the market segment?  
• Which route of administration will lead the market segment? 
• Which end user will lead the market segment? 
• Which distribution channel will lead the market segment? 
• Who are the key players involved in the preeclampsia market? 
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Preeclampsia Market Report Snapshots

Preeclampsia Treatment Companies